Tuberculosis (TB) and HIV/AIDS remain two of the most common causes of death from an infectious disease worldwide 1 . The latest 2014 WHO annual Global TB report estimates that in 2013, there were 9.0 million people (3.3 million women and 500,000 children) who developed TB 2 of which an estimated 1.2 million TB cases (14%) were in people living with HIV. TB imposes a huge burden on the already overstretched health services in sub-Saharan Africa (SSA). Although SSA has 12% of the world's population it generated 29% of the 9 million TB cases and had 254,000 TB related deaths. SSA bears the highest global TB/HIV burden and over 50% of TB cases in SSA are co-infected with HIV 2 . An estimated 1.5 million died from TB globally in 2013, of which a large majority of the 360,000 HIV-positive TB cases who died were from sub-Saharan Africa.
The current WHO estimates on the global burden of TB 2 may represent an underestimate of the actual burden since they are based mainly on calculations from reported TB case notification data and expert opinion about accuracy of reporting. In Africa the actual magnitude of the TB problem remains undefined due to poor laboratory and diagnostics infrastructures, case detection, recording and reporting systems. According to the WHO Report 2 the firstever national survey of the prevalence of TB disease in Nigeria was conducted in 2012 to estimate the prevalence of pulmonary TB among the general adult population. The data from it resulted in a substantial upward revision to WHO estimates of the country's TB disease burden by 200% higher for incidence, 100% higher for prevalence and 400% higher for mortality 2 . Thus numbers of TB cases in SSA need to be defined more accurately since apart from identification of TB cases, there appears to be a large undiagnosed and sub-clinical load of TB as recently shown by studies in the inpatient paediatric 3 , adult 4 and obstetrics wards 5 , at the Research and development is an important pillar of the WHO post-2015 global TB strategy 11 . The overall goal of the strategy is to end the global TB epidemic, with 2035 targets of a 95% reduction in TB deaths and a 90% reduction in TB incidence compared to 2015. Operational research should remain a priority 12,13 and ways to improve optimal delivery of TB and HIV health services, gaining patient confidence, acceptance and adherence to TB care and finding the missing 3 million cases of TB 14 must be found. New research and development into new diagnostic tests, new TB drugs, new treatment regimens which shorten duration of therapy, new regimens for MDR-TB, adjunct treatments, and new TB vaccines may play an important future role in achieving post-2015 global TB targets if any of them will prove to be of practical use for TB management at points of care. Whilst we await major scientific breakthroughs from the current research portfolio, it is of critical importance to note that there are important socio-economic factors coupled with poor housing and health services 12 that are main drivers of the global TB epidemic 15 . Unless these are seriously addressed by the global community and corrected, global TB control will be difficult to achieve and will take a long time.
Meanwhile the huge TB load can be reduced significantly using currently available diagnostic tools and drug regimens if they are used and delivered optimally. Several new TB diagnostics have become available over the past 5 years and some have undergone rapid evaluations in numerous studies 16 . Two new TB drugs, Bedaquiline and Delamanid, have emerged from the TB drug pipeline 17 and are being evaluated in several combinations in trials using adaptive designed for drug sensitive and drug resistant TB and reducing duration of therapy 18 . 22 . As African countries gained independence and local universities were built, African scientists became increasingly empowered to take on the challenges of research on local health problems. The 'annexed site' and 'parachute research' colonial models of research which operated in Africa in the 20 th century were challenged 22 and African scientist led initiatives were initiated, which were successful in developing more equitable research and capacity development south-north partnerships 24 . The past two decades have seen a renaissance of regimens that included weekly administration of high-dose rifapentine and moxifloxacin. Both trials showed that moxifloxacin-containing regimens were not effective in the African setting for shortening therapy to 4 months. Several EDCTP funded evaluations of new TB diagnostics showed that GeneXpert MTB/ RIF Assay is useful in SSA settings to simplify patients' access to early and accurate diagnosis and that it could be used as the initial diagnostic test in individuals suspected of MDR-TB or HIVassociated TB 21 and for more rapid proactive screening for subclinical TB and in paediatric, obstetrics and adult inpatient wards at tertiary care hospitals [3] [4] [5] . An EDCTP-funded a trial of MVA85 vaccine in HIV-infected adults in South Africa and Senegal is ongoing 33 .
The first programme of EDCTP ended in 2014. It made notable and significant investments in TB research and contributed to the establishment of state-of-the-art clinical and diagnostic laboratory infrastructure and training of a range of scientists and health personnel expediting TB related research 33 . So successful was the first EDCTP programme that on December 2nd 2014 there was a historic launch of the second programme (EDCTP2) in Cape Town under the auspices of the European Commission and the South African Department of Science and Technology 37 . EDCTP2 has changed its legal structure from a European Economic Interest Grouping to an Association under Dutch law enabling sub-Saharan African countries to also become full members of EDCTP 38 . This arrangement reflects EDCTP's commitment to equal partnership built on joint ownership, leadership and trust with mutual benefit. Current EDCTP2 membership of the EDCTP Association now includes 13 European countries (Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, The Netherlands, Norway, Portugal, Spain, and United Kingdom) and 13 African countries (Cameroon, Republic of the Congo, The Gambia, Ghana, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda, Mali, Burkina Faso and Zambia). EDCTP2 provides unique and extraordinary opportunities for facilitating and enhancing TB control efforts in SSA. By pooling resources, EDCTP increases coordination of national and regional research programs and reduces fragmentation and duplication. EDCTP2 investments will generate mutually beneficial collaborations among south-north institutions, simultaneously building capacity for conduct of large, multinational projects. Such an approach would enable large research projects that cannot be addressed by a single group and serve the large international footprint characteristic of such endeavors. With African governments as equal partners, close engagement of end-user communities and policy makers will allow national priorities for research to be taken forward and the results of research be translated into policy and practice. EDCTP2 will allow a cohesive program of multidisciplinary research to be undertaken to address some of the key questions that could impact on lowering the burden of TB disease in Africa and worldwide. This will also include high quality research that provides a step up change in our understanding of the optimization of health systems to deliver new or existing evidencebased interventions for the benefit of the peoples of Africa and beyond. EDCTP2 will also allow stimulation of dialogue about biomedical research and its impact on the public in a range of community and industry contexts; promote innovative partnerships between end users, community organizations and the cultural sector, and strengthen capacity to conduct public engagement with biomedical science and health research.
It is also anticipated that EDCTP2 partnerships and investments will lead to establishment and consolidation of an SSA wide resource of collaborating TB and TB/HIV centers, networks and expertise which will foster collaborations, stimulate, and expand basic, translational clinical and applied research, advancing scientific discovery. It is anticipated that more African research leaders will emerge and will lead independent self-perpetuating, African investigator-driven, long-lasting south-north research and training partnerships designed to address issues of local importance, coordinated through the utilization of common standards and practices. This will also ensure that research focusses on regional or national or continental relevant research questions, the answers to which will serve national and regional public health needs and priorities. This will no doubt enhance further development of novel health technologies, novel compounds and drugs from local resources and support multinational multi-disciplinary projects that combine clinical trials, capacity building and networking activities in partnership with European and other countries. The capacity built will also assist in regional and continental public health response to novel and emerging new infectious diseases threats 39 . The overarching goal of the post-2015 WHO TB strategy is to end the global TB epidemic by 2035, with corresponding global targets for a 95% reduction in the number of TB deaths and a 90% reduction in the number of cases by 2035, compared with a baseline of 2015. Milestones for 2020, 2025 and 2030 are also included and that by 2020 no TB patients or their households experience catastrophic costs as a result of their disease. Achieving the proposed targets is based on three strategic pillars: integrated, patient-centered care and prevention; bold policies and supportive systems; and intensified research and innovation. As more African researchers take on leadership positions, it has become important that other funding agencies consider aligning their research and capacity building investments in Africa 40, 41 with EDCTP to have a synergistic and multiplier effect. It is only through empowerment of the next generation of scientific leaders who will conduct the highest level of research that Africa will be able to generate local solutions to local health issues. The case in point here is that solutions for Africa's TB problem should arise from African leadership of scientific research, fully engaged in redressing and resurrecting the imbalances underpinning scientific leadership and bringing equitable relationships with European scientists. 'Holding hands together and moving forward in the fight against killer infectious diseases' is the only way forward to achieve MDG targets. EDCTP2 investments into development of research and capacity in Africa through equitable north-south partnerships far surpasses that of any other 41 and its laudable portfolio provides unique opportunities of leadership of scientific work fully devolving to Africa in TB/HIV and allow post-2015 TB targets to be achieved in SSA.
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